Omeros Corp. began its transformation from a drug development company to a commercial venture Monday after the FDA green-lighted Omidria (phenylephrine and ketorolac injection) 1 percent/0.3 percent. The drug, formerly OMS302, was approved to maintain pupil size during cataract surgery or intraocular lens replacement (ILR) by preventing intraoperative pupil constriction, or miosis, and to reduce postoperative pain.